瑞科生物-B(02179)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02179 瑞科生物-B

未开盘 07-30 13:12:20

5.030

-0.010

-0.20%

最高5.030	最低5.030	成交量0.00
今开5.030	昨收5.040	日振幅0.00%
总市值31.49亿	流通市值23.04亿	总股本6.26亿
成交额0.00	换手率0.00%	流通股本4.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02179","market":"HK","secType":"STK","nameCN":"瑞科生物-B","latestPrice":5.03,"timestamp":1785388340186,"preClose":5.04,"halted":0,"volume":0,"delay":0,"changeRate":-0.001984126984126942,"floatShares":458092178,"shares":626000000,"eps":-1.3367468178716795,"marketStatus":"未开盘","change":-0.01,"latestTime":"07-30 13:12:20","open":5.03,"high":5.03,"low":5.03,"amount":0,"amplitude":0,"askPrice":5.03,"askSize":5000,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.2542172317248192,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785461400000},"marketStatusCode":0,"adr":0,"listingDate":1648656000000,"exchange":"SEHK","adjPreClose":5.04,"openAndCloseTimeList":[[1785375000000,1785384000000],[1785387600000,1785398400000]],"volumeRatio":0,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02179","defaultTab":"news","newsList":[{"id":"1121477892","title":"瑞科生物-B披露带状疱疹及九价HPV疫苗最新研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1121477892","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121477892?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:31","pubTimestamp":1784802662,"startTime":"0","endTime":"0","summary":"2026年7月23日，江蘇瑞科生物技術股份有限公司发布自愿公告，通报旗下带状疱疹疫苗REC610及九价HPV疫苗管线的最新进展。目前，REC610已完成药物临床试验现场检查及药品注册生产现场检查，后续将继续配合监管机构推进审评流程。REC610获受理及完成现场检查并不代表最终可以获批上市；HPV疫苗上市申报时间亦存在变动可能。截至公告披露日，董事会由董事会主席兼非执行董事徐浩宇先生及多名执行、非执行与独立非执行董事组成。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653749666","title":"瑞科生物-B(02179.HK)公布带状疱疹疫苗及九价HPV疫苗研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2653749666","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653749666?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:27","pubTimestamp":1784802474,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158887164","title":"瑞科生物-B更新2026年6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1158887164","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158887164?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:56","pubTimestamp":1782982570,"startTime":"0","endTime":"0","summary":"2026年7月2日，瑞科生物-B发布2026年6月截至月报表。报告显示，截至2026年6月30日，公司注册股本总计人民币626,075,702元，包含内资股167,983,524股和H股458,092,178股，面值均为人民币1元，较上月结存数未发生变化。公告披露，报告期内，瑞科生物-B未进行任何新增发行、股份回购或注销，公司股本维持不变。同时，公告明确指出截至2026年6月底，公司已满足香港联合交易所有限公司相关上市规则中关于公众持股量的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117744616","title":"瑞科生物-B公布2026年5月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1117744616","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117744616?lang=zh_cn&edition=full","pubTime":"2026-06-01 12:10","pubTimestamp":1780287037,"startTime":"0","endTime":"0","summary":"江苏瑞科生物技术股份有限公司于2026年6月1日公布了截至2026年5月31日的证券变动月报表。报告显示，截止本月末，公司未出现新增发行、股份购回、注销及库藏股变动，股本结构保持稳定。报告同时指出，瑞科生物-B无任何股份期权计划及可换股票据变动，亦无其他股份相关协议或安排的变动。根据公告，瑞科生物-B已严格遵守香港联交所《上市规则》以及适用的法律及监管规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120310362","title":"瑞科生物-B更新4月股份变动月报表，内资股与外资股转换为H股，总股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1120310362","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120310362?lang=zh_cn&edition=full","pubTime":"2026-05-05 16:36","pubTimestamp":1777970211,"startTime":"0","endTime":"0","summary":"江苏瑞科生物技术股份有限公司于2026年5月5日发布了2026年4月的股份变动月报表，披露了报告期内各类股份以及注册股本的变动情况。报告期起止日为2026年4月1日至2026年4月30日。根据公告，报告期初内资股297,937,013股、非上市外资股12,000,000股及H股316,138,689股，合计626,075,702股。2026年4月29日，公司将129,953,489股内资股和12,000,000股非上市外资股转换为141,953,489股H股，从而使得本月末内资股数为167,983,524股，非上市外资股为0股，H股上升至458,092,178股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115951619","title":"瑞科生物-B：4月29日完成141,953,489股转换为H股，已发行股本相应变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1115951619","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115951619?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:26","pubTimestamp":1777551999,"startTime":"0","endTime":"0","summary":"江蘇瑞科生物技術股份有限公司于2026年4月30日发布公告，指出公司已于4月29日将129,953,489股内资股与12,000,000股未上市外资股合计转换成141,953,489股H股。该转换数量占转换前已发行H股总数约44.9%。本次转换完成后，公司H股由316,138,689股增至458,092,178股；内资股由297,937,013股降至167,983,524股；未上市外资股则由12,000,000股降至0股，总发行股本仍维持626,075,702股不变。公司同时确认，本次股份变动已获得董事会正式授权，且符合所有适用的上市规则及相关法例。公告由董事刘勇签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"瑞科生物-B：4月29日完成141,953,489股转换为H股，已发行股本相应变动","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631328846","title":"瑞科生物-B(02179)：完成H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2631328846","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631328846?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:17","pubTimestamp":1777551457,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞科生物-B(02179)发布公告，已于2026年4月29日完成将合共1.42亿股未上市股份转换为H股，而转换后H股于2026年4月30日上午九时正于联交所开始上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02179","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631579379","title":"瑞科生物-B(02179)股东将股票存入中国证券登记结算香港 存仓市值6.59亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631579379","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631579379?lang=zh_cn&edition=full","pubTime":"2026-04-30 08:20","pubTimestamp":1777508409,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，4月29日，瑞科生物-B(02179)股东将股票存入中国证券登记结算香港，存仓市值6.59亿港元，占比41.11%。此前瑞科生物-B发布截至2025年12月31日止年度业绩，收入人民币1272.6万元;股东应占亏损6.1亿元，同比扩大8.54%;每股亏损1.15元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02179","BK1161","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153673563","title":"瑞科生物-B(02179)2025年首年实现疫苗商业化收入 高研发投入助力核心产品落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1153673563","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153673563?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:27","pubTimestamp":1777462064,"startTime":"0","endTime":"0","summary":"2025年度，瑞科生物-B录得首次产品商业化收入12.73亿元人民币，2024年度尚未产生收入。销售成本为1.49亿元，毛利为11.23亿元。同年其他收入及收益为2.07亿元，上年同期为0.62亿元。研发开支增至5.21亿元，上一年度为4.76亿元；销售及分销开支为1.56亿元，管理费用为0.91亿元，财务成本为0.03亿元。全年税前亏损6.08亿元，2024年度则为5.62亿元；最终年内亏损为6.10亿元，同比有所扩大。每股基本及摊薄亏损为1.15元人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞科生物-B(02179)2025年首年实现疫苗商业化收入 高研发投入助力核心产品落地","news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147177428","title":"瑞科生物-B2026年3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1147177428","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147177428?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:32","pubTimestamp":1775035934,"startTime":"0","endTime":"0","summary":"江蘇瑞科生物技術股份有限公司于2026年4月1日发布2026年3月股份变动月报表。公告显示，截至2026年3月31日，各类股份无新增发行、购回、注销或库藏股变动，股本结构保持不变。江蘇瑞科生物技術股份有限公司报告期内的注册股本总额为人民币626,075,702元，具体包括297,937,013股内资股、12,000,000股非上市外资股及316,138,689股H股，面值均为每股人民币1元。公告同时披露，当月未发生期权、股权激励计划或可转换债券等相关变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622526011","title":"瑞科生物-B(02179)发布年度业绩 股东应占亏损6.1亿元 同比扩大8.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622526011","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622526011?lang=zh_cn&edition=full","pubTime":"2026-03-25 07:10","pubTimestamp":1774393810,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞科生物-B 发布截至2025年12月31日止年度业绩，收入人民币1272.6万元;股东应占亏损6.1亿元，同比扩大8.54%;每股亏损1.15元。目前处于试生产阶段，匹配九价HPV疫苗临床研究进展以支持中国BLA申请。此外，公司已于2021年11月完成了基于CHO细胞表达系统的创新疫苗生产基地的建设，顺利取得由江苏省药监局颁发的疫苗生产许可证。该生产基地连续多年获得由欧盟质量授权人签发的符合性声明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"瑞科生物-B(02179)发布年度业绩 股东应占亏损6.1亿元 同比扩大8.54%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02179","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095612","title":"瑞科生物-B(02179)：魏其芳、孙嘉恩获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095612","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095612?lang=zh_cn&edition=full","pubTime":"2026-03-24 22:41","pubTimestamp":1774363309,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞科生物-B(02179)发布公告，翁美仪女士(翁女士)已辞任本公司公司秘书、香港联合交易所有限公司(联交所”证券上市规则第 3.05条项下本公司授权代表及香港法例第622章公司条例第16部和上市规则第 19A.13(2)条项下代表本公司在香港接受送达的法律程序文件及通知书的香港法律程序文件代理人(法律程序文件代理人)，自2026年3月24日起生效。本公司已委任魏其芳先生(魏先生)及孙嘉恩女士(孙女士)担任本公司联席公司秘书，已委任魏先生担任授权代表，及已委任孙女士担任法律程序文件代理人，均自2026年3月24日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618386471","title":"瑞科生物-B(02179.HK)拟3月24日举行董事会会议审批全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618386471","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618386471?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:57","pubTimestamp":1773309422,"startTime":"0","endTime":"0","summary":"格隆汇3月12日丨瑞科生物-B(02179.HK)宣布，董事会会议将于2026年3月24日(星期二)举行，藉以(其中包括)审议及批准公司及其附属公司截至2025年12月31日止年度的全年业绩及其发布，并考虑派发末期股息(如有)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260312/32063734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02179","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168337064","title":"瑞科生物（02179）2月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1168337064","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168337064?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:58","pubTimestamp":1772441887,"startTime":"0","endTime":"0","summary":"江蘇瑞科生物技術股份有限公司（02179）于2026年3月2日发布截至2026年2月28日的股份变动月报表。报告显示，公司本月内未发生新增股份发行、回购、注销或库藏股变动，整体股本结构保持不变。\n根据公告，截至2026年2月28日，公司内资股数量为297,937,013股，非上市外资股数量为12,000,000股，H股数量则为316,138,689股。公司注册股本合计626,075,702元人民币。上述数据与上月结存保持一致，未见增减。\n公司在公告中声明，已遵守香港联合交易所有限公司《上市规则》及相关法律规定，未出现违反监管要求的情况。公告由董事刘勇签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609757567","title":"瑞科生物-B(02179):联交所就公司H股全流通计划授出上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2609757567","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609757567?lang=zh_cn&edition=full","pubTime":"2026-02-06 19:33","pubTimestamp":1770377606,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞科生物-B(02179)发布公告，公司已收到联交所于2026年2月5日授出的就1.42亿股H股上市及买卖的批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞科生物-B(02179):联交所就公司H股全流通计划授出上市批准","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154937651","title":"瑞科生物（02179）更新1月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1154937651","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154937651?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:03","pubTimestamp":1770022995,"startTime":"0","endTime":"0","summary":"江蘇瑞科生物技術股份有限公司（“瑞科生物”，02179）于2026年2月2日发布2026年1月股份变动月报表。公告显示，截至1月底，公司注册股本总额为人民币626,075,702元，其中内资股297,937,013股、非上市外资股12,000,000股、已发行H股316,138,689股，各类股份数量与上月保持一致。\n根据月报，本月未发生新增股份发行、购回或注销，也未出现库存股变动。公司确认已遵守香港联交所《上市规则》和相关法律法规。本次公告由董事刘勇签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608288026","title":"瑞科生物-B：中国证监会就公司H股全流通计划出具备案通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608288026","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608288026?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:58","pubTimestamp":1769993880,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　瑞科生物-B（02179）发布公告，公司已于近期收到中国证监会就本次H股全流通向公司出具的日期为2026年1月13日的备案通知书。根据备案通知书，公司已就28名股东所持有的合计1.42亿股未上市股份转换为H股完成向中国证监会作出备案。备案通知书自2026年1月13日起12个月内有效。公司将向联交所申请批准相关H股上市及买卖。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-02-02/doc-inhkkquq8154370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02179","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607041707","title":"瑞科生物-B(02179)：中国证监会就公司H股全流通计划出具备案通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2607041707","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607041707?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:42","pubTimestamp":1769784157,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞科生物-B(02179)发布公告，公司已于近期收到中国证监会就本次H股全流通向公司出具的日期为2026年1月13日的备案通知书。根据备案通知书，公司已就28名股东所持有的合计1.42亿股未上市股份转换为H股完成向中国证监会作出备案。备案通知书自2026年1月13日起12个月内有效。公司将向联交所申请批准相关H股上市及买卖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400130.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞科生物-B(02179)：中国证监会就公司H股全流通计划出具备案通知书","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02179","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606675718","title":"瑞科生物境内未上市股份“全流通”获中国证监会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2606675718","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606675718?lang=zh_cn&edition=full","pubTime":"2026-01-28 09:26","pubTimestamp":1769563599,"startTime":"0","endTime":"0","summary":"南方财经1月28日电，中国证监会国际合作司发布关于江苏瑞科生物技术股份有限公司境内未上市股份“全流通”备案通知书，公司28名股东拟将所持合计141,953,489股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601283633137679.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601283633137679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02179","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514870636","title":"瑞科生物-B(02179)定向发行内资股申请材料获中国证监会受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2514870636","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514870636?lang=zh_cn&edition=full","pubTime":"2025-02-27 19:21","pubTimestamp":1740655278,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞科生物-B(02179)发布公告，有关(其中包括)本公司建议定向发行内资股及其相关事宜已获临时股东大会审议批准的相关事宜。本公司于近日收到中国证监会出具的《中国证监会行政许可申请受理单》(受理序号：250162)。中国证监会依法对本公司提交的申请材料进行了审查，认为该申请材料齐全，决定对该行政许可申请予以受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02179","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0702},{"period":"3month","weight":-0.0308},{"period":"6month","weight":0.004},{"period":"1year","weight":-0.3881},{"period":"ytd","weight":0.2575}],"compareEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":0.1301},{"period":"3month","weight":0.0032},{"period":"6month","weight":-0.0558},{"period":"1year","weight":0.0271},{"period":"ytd","weight":0.0089}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏瑞科生物技术股份有限公司是一家从事疫苗研发的中国公司。该公司尚处于研发阶段。该公司的疫苗管线包括重组九价人乳头瘤病毒（HPV）、新佐剂重组九价HPV疫苗、重组二价（16/18）HPV疫苗、重组二价（6/11）HPV疫苗、新佐剂重组四价HPV疫苗、新佐剂重组带状疱疹病疫苗、新佐剂重组呼吸道合胞病毒疫苗、重组偏肺病毒疫苗、重组人巨细胞病毒疫苗、重组双组分新冠病毒疫苗、重组乙型肝炎病毒疫苗等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.009257},{"month":2,"riseRate":0.25,"avgChangeRate":-0.058747},{"month":3,"riseRate":0.25,"avgChangeRate":-0.071963},{"month":4,"riseRate":0.4,"avgChangeRate":-0.012446},{"month":5,"riseRate":0.2,"avgChangeRate":-0.039249},{"month":6,"riseRate":0.2,"avgChangeRate":-0.012707},{"month":7,"riseRate":0.6,"avgChangeRate":0.000991},{"month":8,"riseRate":0.25,"avgChangeRate":-0.033938},{"month":9,"riseRate":0.25,"avgChangeRate":-0.012227},{"month":10,"riseRate":0.5,"avgChangeRate":0.027812},{"month":11,"riseRate":0,"avgChangeRate":-0.140794},{"month":12,"riseRate":0.75,"avgChangeRate":0.059254}],"exchange":"SEHK","name":"瑞科生物-B","nameEN":"RECBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞科生物-B(02179)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞科生物-B(02179)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞科生物-B,02179,瑞科生物-B股票,瑞科生物-B股票老虎,瑞科生物-B股票老虎国际,瑞科生物-B行情,瑞科生物-B股票行情,瑞科生物-B股价,瑞科生物-B股市,瑞科生物-B股票价格,瑞科生物-B股票交易,瑞科生物-B股票购买,瑞科生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞科生物-B(02179)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞科生物-B(02179)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}